Consun Pharmaceutical Group Ltd. (1681) AI Stock Analysis

• Market Cap: €10.71B
• Dividend Yield: 4.66%
• Average Volume (3M): 2.09M
• Price to Earnings (P/E): 10.7
• Beta (1Y): 0.55
• Revenue Growth: 12.70%
• EPS Growth: 9.91%
• Country: HK
• Employees: 3,164
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.66
• Shares Outstanding: 852,617,400
• 10 Day Avg. Volume: 2,810,323
• 30 Day Avg. Volume: 2,088,510
• PEG Ratio: 1.47
• Price to Book (P/B): 2.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 29.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.01
• Price Target Upside: -22.26% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 79 Outperform
• Price Target: HK$14.00 ▲(8.70%Upside)

Consun Pharmaceutical Group Ltd. receives a high overall score driven by strong financial performance and attractive valuation, with an emphasis on robust revenue growth, profitability, and a compelling P/E ratio combined with a high dividend yield. While bullish technical indicators are present, caution is advised due to overbought signals. Lack of recent cash flow data and earnings call analysis slightly limits the assessment.

Positive Factors

New Product Development

Potential introduction of new drugs, with focus areas being identified, could be a catalyst and drive sales growth ahead.

Risk Reduction

Recent exclusion in the national tender of finished Chinese medicines indicates lower risk on price cut for its key product uremic clearance granule (UCG) in the next 2 years.

Negative Factors

Economic Impact

Sales volume growth slowdown due to a slowing economy.

Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model

Company Description

Consun Pharmaceutical Group Ltd. (1681) is a China-based pharmaceutical company engaged in the research, development, manufacturing, and marketing of modern Chinese medicines and medical contrast medium products. The company primarily focuses on nephrology, orthopedics, and dermatology sectors, providing a diverse range of therapeutic solutions aimed at addressing specific medical needs. Consun Pharmaceutical is recognized for its innovation in traditional Chinese medicine formulations, integrating modern scientific approaches to enhance efficacy and safety.

How the Company Makes Money

Consun Pharmaceutical Group Ltd. generates revenue through the sale of its pharmaceutical products, primarily focusing on modern Chinese medicines and medical contrast medium products. The company's key revenue streams include the domestic market in China, where it distributes its products through a network of distributors and direct sales to hospitals and pharmacies. Consun leverages its research and development capabilities to enhance its product offerings and maintain a competitive edge in the market. The company may also engage in strategic partnerships, licensing agreements, and collaborations to expand its product reach and enhance its market position, although specific details on partnerships are not provided.

Consun Pharmaceutical Group Ltd. Financial Statement Overview

Summary

Consun Pharmaceutical Group Ltd. demonstrates strong revenue growth and profitability margins, with a robust balance sheet and improved equity position. However, cash flow analysis is limited due to missing recent data, and high cash reserves suggest potential underutilization of funds.

Income Statement

Consun Pharmaceutical Group Ltd. has demonstrated strong growth in revenue, consistently increasing from 2019 to 2024. The company shows impressive profitability with a gross profit margin consistently above 75% and a net profit margin improving from 4.6% in 2019 to 30.7% in 2024. EBIT and EBITDA margins have also shown positive trends, indicating effective cost management. However, the high growth rate may pose sustainability challenges in future periods.

Balance Sheet

The company maintains a robust balance sheet with a strong equity position and increasing total assets. The debt-to-equity ratio has improved, reflecting reduced leverage over the years. The return on equity has also improved significantly, indicating efficient use of equity capital. Nonetheless, high cash reserves might suggest underutilization of funds, which could be optimized for growth or shareholder returns.

Cash Flow

Consun Pharmaceutical Group Ltd. has maintained positive free cash flow consistently, although recent data is unavailable for comprehensive analysis. The company has shown the ability to generate cash from operations, but the lack of recent cash flow data limits a full assessment. Historical trends suggest sound cash flow management, but recent growth in free cash flow percentages are needed for a clearer picture.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.97B	2.59B	2.34B	2.04B	1.75B
Gross Profit	2.24B	1.92B	1.76B	1.53B	1.32B
EBITDA	1.05B	963.06M	785.89M	728.71M	618.79M
Net Income	910.46M	784.53M	682.91M	590.17M	498.79M
Balance Sheet
Total Assets	5.85B	5.51B	4.89B	4.36B	3.95B
Cash, Cash Equivalents and Short-Term Investments	3.87B	3.58B	3.04B	2.43B	1.94B
Total Debt	267.17M	511.53M	460.18M	610.97M	549.41M
Total Liabilities	1.46B	1.59B	1.45B	1.45B	1.43B
Stockholders Equity	4.10B	3.63B	3.15B	2.62B	2.22B
Cash Flow
Free Cash Flow	977.99M	766.41M	896.09M	627.29M	818.36M
Operating Cash Flow	1.09B	818.97M	947.68M	725.54M	867.06M
Investing Cash Flow	-186.91M	-231.77M	-368.80M	-298.31M	-25.70M
Financing Cash Flow	-729.26M	-280.10M	-342.20M	-166.66M	-279.80M

Consun Pharmaceutical Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Positive. The current price of 12.88 is above the 20-day moving average (MA) of 11.76, above the 50-day MA of 11.11, and above the 200-day MA of 8.87, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 86.02 is Negative, neither overbought nor oversold. The STOCH value of 95.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1681.

Consun Pharmaceutical Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1681	79 Outperform	€10.71B	10.70	23.28%	4.66%	12.70%	9.91%
2877	74 Outperform	HK$6.35B	6.97	11.61%	0.83%	-18.09%	-15.08%
0719	70 Outperform	HK$11.19B	12.29	8.89%	0.58%	4.91%	-11.80%
1558	65 Neutral	HK$14.96B	26.93	5.88%	―	-42.02%	-76.29%
Sector *	60 Neutral	HK$17.07B	5.63	-7.44%	2.87%	11.55%	-28.15%
0570	58 Neutral	$11.83B	200.00	0.25%	0.44%	-10.72%	-95.88%
0460	49 Neutral	HK$12.41B	―	-4.93%	1.58%	-0.11%	-290.77%

Consun Pharmaceutical Group Ltd. Corporate Events

Consun Pharmaceutical Group Announces Board Composition and Committee Roles

Consun Pharmaceutical Group Ltd. has announced the composition of its Board of Directors and the roles within its four established committees. This organizational update may influence the company’s governance and strategic direction, potentially impacting stakeholders and the company’s positioning in the pharmaceutical industry.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Ltd. Forms Nomination Committee to Strengthen Governance

Consun Pharmaceutical Group Ltd. has announced the establishment of a Nomination Committee within its Board of Directors, effective from June 2025. This committee, primarily composed of independent non-executive directors, will oversee the nomination process for board members, ensuring diversity and independence in its composition. The move is aimed at enhancing corporate governance and ensuring a robust selection process for board appointments.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Updates Nomination Committee for Enhanced Governance

Consun Pharmaceutical Group Ltd. announced changes in its Nomination Committee, effective June 20, 2025, with Mr. An Meng stepping down and Dr. Zhang Lihua joining as a member. This change aligns with the updated Corporate Governance Code and aims to enhance the company’s governance practices, thereby potentially improving its overall performance and diversity.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Launches HKD200 Million Share Repurchase Program

Consun Pharmaceutical Group Ltd. has announced a share repurchase program, utilizing a general mandate granted by shareholders. The program aims to repurchase up to HKD200 million worth of shares from the open market, reflecting the company’s confidence in its business prospects and belief that its current share price undervalues its intrinsic worth. This initiative is aligned with the company’s long-term strategy to optimize capital structure and enhance shareholder value, while maintaining sufficient financial resources for ongoing operations.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Successfully Passes AGM Resolutions

Consun Pharmaceutical Group Ltd. announced the successful passage of all proposed resolutions at its Annual General Meeting held on May 22, 2025. Key resolutions included the approval of the financial statements for 2024, re-election of several directors, declaration of a final dividend, and re-appointment of KPMG as auditors. The results reflect strong shareholder support and are likely to positively impact the company’s governance and financial strategies.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$7.80 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical’s Traditional Chinese Medicine Product Gains Protected Status

Consun Pharmaceutical Group Ltd. announced that its product, Kidney Repair and Edema Alleviation Granules, has been approved as a Class 2 Protected Product of Traditional Chinese Medicine by the National Medical Products Administration. This approval grants the product a state protection period of seven years, during which other enterprises are prohibited from imitating it. The recognition is expected to support the company’s long-term development and strengthen its market position.